Polycystic Ovary Syndrome Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:

PUBLISHED: December 28, 2023

PAGES: 306 Pages

DELIVERY TIME: 2-5 business days

ADD TO COMPARE

SELECT AN OPTION

Description

The global polycystic ovary syndrome (PCOS) treatment market, valued at US$ 4.2 billion at the end of 2024, is forecasted to witness substantial growth, with an estimated valuation of US$ 6.11 billion by 2031. PCOS, a complex endocrine condition affecting women, is characterized by ovarian cysts, subfertility, and endocrine variations.

PCOS: A Global Health Concern

Polycystic ovarian syndrome (PCOS) poses a significant global health challenge, affecting millions of women worldwide. According to the World Health Organization (WHO), over 116 million women (3.4%) globally suffer from PCOS. In the United States alone, PCOS accounts for 6% to 12% of cases among women of reproductive age, making it a leading cause of female infertility.

PCOS is not limited to a specific age group, as it can persist even in postmenopausal women, leading to metabolic changes and an increased risk of cardiovascular disease. Early diagnosis and treatment are crucial not only to alleviate symptoms but also to prevent long-term consequences.

Opportunities for PCOS Drug Manufacturers:

Changing Lifestyles and Rising Awareness: With a growing awareness of PCOS and its associated risks, there is an increasing demand for diagnosis and treatment. Awareness programs and initiatives, such as PCOS Awareness Association (PCOSAA), are contributing to higher diagnosis rates.

Innovative Treatment Modalities: Manufacturers are offering an expanded range of drug formulations and dietary products to cater to the rising number of PCOS diagnoses. Innovative alternatives and improved treatment options are expected to boost adoption rates.

Challenges Faced by Market Players:

Unavailability of FDA-Approved Drugs: Limited FDA-approved drugs for PCOS treatment force individuals to use off-label drugs intended for different purposes. The absence of FDA-approved treatments for PCOS-related symptoms hinders market growth.

Lack of Awareness in Underdeveloped Economies: In underdeveloped economies, awareness regarding PCOS and its symptoms remains significantly low. This, coupled with a lack of understanding and a carefree attitude towards treatment, can hinder market expansion.

Country-Wise Insights:

Lucrative U.S. Market: The United States experiences rising healthcare costs and an increasing prevalence of PCOS-related disorders. Improved healthcare infrastructure, rising disposable income, and government-led awareness initiatives contribute to market growth.

Growing Indian Market: India has witnessed a surge in PCOS diagnoses, with approximately 22.5% of women affected. Increased awareness, changing lifestyles, and dietary habits are driving the demand for PCOS treatment in the country.

Competitive Landscape:

Leading manufacturers and pharmaceutical companies are focusing on developing innovative products to strengthen their global product pipelines. Collaborations and consolidation activities with other firms are being pursued to expedite research, development, and distribution.

Key Companies Profiled:

Novartis AG
Sanofi
Teva Pharmaceutical Industries Limited
Merck & Co., Inc. (Merck group)
AstraZeneca plc.
Bayer AG
Abbott
Pfizer, Inc
Bristol-Myer Squibb Company
Ferring Pharmaceuticals, Inc.
Johnson and Johnson
Mylan N.V.
Allergan plc.
GlaxoSmithKline
Lupin Pharmaceuticals
AbbVie
Takeda
BIOCAD Global
Blairex Laboratories Inc
Agile Therapeutics

Key Segments of PCOS Treatment Industry Research

By Drug Class:

Oral Contraceptives
Insulin Sensitizing Agents
Antidepressants
Ornithine Decarboxylase Inhibitors
Aromatase Inhibitors & SERMs
Diuretics

By Distribution Channel:

Hospital Pharmacies
Drug Stores/OTC
e-Commerce
Clinics

By Region:

North America
Latin America
Europe Polycystic
South Asia
East Asia
Oceania
Middle East & Africa

1. Executive Summary

1.1. Global Polycystic Ovary Syndrome (PCOS) Treatment Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
- 2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, 2018 - 2031

3.1. Global Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
- 3.1.1. Key Highlights
  - 3.1.1.1. Oral Contraceptives
  - 3.1.1.2. Insulin Sensitizing Agents
  - 3.1.1.3. Antidepressants
  - 3.1.1.4. Ornithine Decarboxylase Inhibitors
  - 3.1.1.5. Aromatase Inhibitors & SERMs
  - 3.1.1.6. Diuretics
3.2. Global Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 3.2.1. Key Highlights
  - 3.2.1.1. Hospital Pharmacies
  - 3.2.1.2. Drug Stores/OTC
  - 3.2.1.3. e-Commerce
  - 3.2.1.4. Clinics
3.3. Global Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
- 3.3.1. Key Highlights
  - 3.3.1.1. North America
  - 3.3.1.2. Europe
  - 3.3.1.3. Asia Pacific
  - 3.3.1.4. Latin America
  - 3.3.1.5. Middle East & Africa

4. North America Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, 2018 - 2031

4.1. North America Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
- 4.1.1. Key Highlights
  - 4.1.1.1. Oral Contraceptives
  - 4.1.1.2. Insulin Sensitizing Agents
  - 4.1.1.3. Antidepressants
  - 4.1.1.4. Ornithine Decarboxylase Inhibitors
  - 4.1.1.5. Aromatase Inhibitors & SERMs
  - 4.1.1.6. Diuretics
4.2. North America Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 4.2.1. Key Highlights
  - 4.2.1.1. Hospital Pharmacies
  - 4.2.1.2. Drug Stores/OTC
  - 4.2.1.3. e-Commerce
  - 4.2.1.4. Clinics
- 4.2.2. BPS Analysis/Market Attractiveness Analysis
4.3. North America Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 4.3.1. Key Highlights
  - 4.3.1.1. U.S. Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 4.3.1.2. U.S. Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 4.3.1.3. Canada Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 4.3.1.4. Canada Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, 2018 - 2031

5.1. Europe Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
- 5.1.1. Key Highlights
  - 5.1.1.1. Oral Contraceptives
  - 5.1.1.2. Insulin Sensitizing Agents
  - 5.1.1.3. Antidepressants
  - 5.1.1.4. Ornithine Decarboxylase Inhibitors
  - 5.1.1.5. Aromatase Inhibitors & SERMs
  - 5.1.1.6. Diuretics
5.2. Europe Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 5.2.1. Key Highlights
  - 5.2.1.1. Hospital Pharmacies
  - 5.2.1.2. Drug Stores/OTC
  - 5.2.1.3. e-Commerce
  - 5.2.1.4. Clinics
- 5.2.2. BPS Analysis/Market Attractiveness Analysis
5.3. Europe Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 5.3.1. Key Highlights
  - 5.3.1.1. Germany Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 5.3.1.2. Germany Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.3.1.3. U.K. Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 5.3.1.4. U.K. Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.3.1.5. France Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 5.3.1.6. France Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.3.1.7. Italy Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 5.3.1.8. Italy Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.3.1.9. Turkey Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 5.3.1.10. Turkey Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.3.1.11. Russia Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 5.3.1.12. Russia Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.3.1.13. Rest of Europe Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 5.3.1.14. Rest of Europe Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, 2018 - 2031

6.1. Asia Pacific Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
- 6.1.1. Key Highlights
  - 6.1.1.1. Oral Contraceptives
  - 6.1.1.2. Insulin Sensitizing Agents
  - 6.1.1.3. Antidepressants
  - 6.1.1.4. Ornithine Decarboxylase Inhibitors
  - 6.1.1.5. Aromatase Inhibitors & SERMs
  - 6.1.1.6. Diuretics
6.2. Asia Pacific Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 6.2.1. Key Highlights
  - 6.2.1.1. Hospital Pharmacies
  - 6.2.1.2. Drug Stores/OTC
  - 6.2.1.3. e-Commerce
  - 6.2.1.4. Clinics
- 6.2.2. BPS Analysis/Market Attractiveness Analysis
6.3. Asia Pacific Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 6.3.1. Key Highlights
  - 6.3.1.1. China Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 6.3.1.2. China Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.3.1.3. Japan Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 6.3.1.4. Japan Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.3.1.5. South Korea Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 6.3.1.6. South Korea Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.3.1.7. India Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 6.3.1.8. India Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.3.1.9. Southeast Asia Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 6.3.1.10. Southeast Asia Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.3.1.11. Rest of Asia Pacific Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 6.3.1.12. Rest of Asia Pacific Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, 2018 - 2031

7.1. Latin America Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
- 7.1.1. Key Highlights
  - 7.1.1.1. Oral Contraceptives
  - 7.1.1.2. Insulin Sensitizing Agents
  - 7.1.1.3. Antidepressants
  - 7.1.1.4. Ornithine Decarboxylase Inhibitors
  - 7.1.1.5. Aromatase Inhibitors & SERMs
  - 7.1.1.6. Diuretics
7.2. Latin America Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 7.2.1. Key Highlights
  - 7.2.1.1. Hospital Pharmacies
  - 7.2.1.2. Drug Stores/OTC
  - 7.2.1.3. e-Commerce
  - 7.2.1.4. Clinics
- 7.2.2. BPS Analysis/Market Attractiveness Analysis
7.3. Latin America Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 7.3.1. Key Highlights
  - 7.3.1.1. Brazil Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 7.3.1.2. Brazil Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 7.3.1.3. Mexico Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 7.3.1.4. Mexico Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 7.3.1.5. Argentina Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 7.3.1.6. Argentina Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 7.3.1.7. Rest of Latin America Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 7.3.1.8. Rest of Latin America Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, 2018 - 2031

8.1. Middle East & Africa Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
- 8.1.1. Key Highlights
  - 8.1.1.1. Oral Contraceptives
  - 8.1.1.2. Insulin Sensitizing Agents
  - 8.1.1.3. Antidepressants
  - 8.1.1.4. Ornithine Decarboxylase Inhibitors
  - 8.1.1.5. Aromatase Inhibitors & SERMs
  - 8.1.1.6. Diuretics
8.2. Middle East & Africa Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 8.2.1. Key Highlights
  - 8.2.1.1. Hospital Pharmacies
  - 8.2.1.2. Drug Stores/OTC
  - 8.2.1.3. e-Commerce
  - 8.2.1.4. Clinics
- 8.2.2. BPS Analysis/Market Attractiveness Analysis
8.3. Middle East & Africa Polycystic Ovary Syndrome (PCOS) Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 8.3.1. Key Highlights
  - 8.3.1.1. GCC Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 8.3.1.2. GCC Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.3.1.3. South Africa Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 8.3.1.4. South Africa Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.3.1.5. Egypt Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 8.3.1.6. Egypt Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.3.1.7. Nigeria Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 8.3.1.8. Nigeria Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.3.1.9. Rest of Middle East & Africa Polycystic Ovary Syndrome (PCOS) Treatment Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 8.3.1.10. Rest of Middle East & Africa Polycystic Ovary Syndrome (PCOS) Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. By Drug Class vs by Distribution Channel Heatmap
9.2. Company Market Share Analysis, 2023
9.3. Competitive Dashboard
9.4. Company Profiles
- 9.4.1. Novartis AG
  - 9.4.1.1. Company Overview
  - 9.4.1.2. Therapy Portfolio
  - 9.4.1.3. Financial Overview
  - 9.4.1.4. Business Strategies and Development
- 9.4.2. Sanofi
  - 9.4.2.1. Company Overview
  - 9.4.2.2. Therapy Portfolio
  - 9.4.2.3. Financial Overview
  - 9.4.2.4. Business Strategies and Development
- 9.4.3. Teva Pharmaceutical Industries Limited
  - 9.4.3.1. Company Overview
  - 9.4.3.2. Therapy Portfolio
  - 9.4.3.3. Financial Overview
  - 9.4.3.4. Business Strategies and Development
- 9.4.4. Merck & Co., Inc. (Merck group)
  - 9.4.4.1. Company Overview
  - 9.4.4.2. Therapy Portfolio
  - 9.4.4.3. Financial Overview
  - 9.4.4.4. Business Strategies and Development
- 9.4.5. AstraZeneca plc.
  - 9.4.5.1. Company Overview
  - 9.4.5.2. Therapy Portfolio
  - 9.4.5.3. Financial Overview
  - 9.4.5.4. Business Strategies and Development
- 9.4.6. Bayer AG
  - 9.4.6.1. Company Overview
  - 9.4.6.2. Therapy Portfolio
  - 9.4.6.3. Financial Overview
  - 9.4.6.4. Business Strategies and Development
- 9.4.7. Abbott
  - 9.4.7.1. Company Overview
  - 9.4.7.2. Therapy Portfolio
  - 9.4.7.3. Financial Overview
  - 9.4.7.4. Business Strategies and Development
- 9.4.8. Pfizer, Inc
  - 9.4.8.1. Company Overview
  - 9.4.8.2. Therapy Portfolio
  - 9.4.8.3. Financial Overview
  - 9.4.8.4. Business Strategies and Development
- 9.4.9. Bristol-Myer Squibb Company
  - 9.4.9.1. Company Overview
  - 9.4.9.2. Therapy Portfolio
  - 9.4.9.3. Financial Overview
  - 9.4.9.4. Business Strategies and Development
- 9.4.10. Ferring Pharmaceuticals, Inc.
  - 9.4.10.1. Company Overview
  - 9.4.10.2. Therapy Portfolio
  - 9.4.10.3. Financial Overview
  - 9.4.10.4. Business Strategies and Development
- 9.4.11. Johnson and Johnson
  - 9.4.11.1. Company Overview
  - 9.4.11.2. Therapy Portfolio
  - 9.4.11.3. Financial Overview
  - 9.4.11.4. Business Strategies and Development
- 9.4.12. Mylan N.V.
  - 9.4.12.1. Company Overview
  - 9.4.12.2. Therapy Portfolio
  - 9.4.12.3. Financial Overview
  - 9.4.12.4. Business Strategies and Development
- 9.4.13. Allergan plc.
  - 9.4.13.1. Company Overview
  - 9.4.13.2. Therapy Portfolio
  - 9.4.13.3. Financial Overview
  - 9.4.13.4. Business Strategies and Development
- 9.4.14. GlaxoSmithKline
  - 9.4.14.1. Company Overview
  - 9.4.14.2. Therapy Portfolio
  - 9.4.14.3. Financial Overview
  - 9.4.14.4. Business Strategies and Development
- 9.4.15. Lupin Pharmaceuticals
  - 9.4.15.1. Company Overview
  - 9.4.15.2. Therapy Portfolio
  - 9.4.15.3. Financial Overview
  - 9.4.15.4. Business Strategies and Development
- 9.4.16. AbbVie
  - 9.4.16.1. Company Overview
  - 9.4.16.2. Therapy Portfolio
  - 9.4.16.3. Financial Overview
  - 9.4.16.4. Business Strategies and Development
- 9.4.17. Takeda
  - 9.4.17.1. Company Overview
  - 9.4.17.2. Therapy Portfolio
  - 9.4.17.3. Financial Overview
  - 9.4.17.4. Business Strategies and Development
- 9.4.18. BIOCAD Global
  - 9.4.18.1. Company Overview
  - 9.4.18.2. Therapy Portfolio
  - 9.4.18.3. Financial Overview
  - 9.4.18.4. Business Strategies and Development
- 9.4.19. Blairex Laboratories Inc
  - 9.4.19.1. Company Overview
  - 9.4.19.2. Therapy Portfolio
  - 9.4.19.3. Financial Overview
  - 9.4.19.4. Business Strategies and Development